 | |
 Avanafil is aPDE5 inhibitor | |
| Clinical data | |
|---|---|
| Trade names | Stendra |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a614010 |
| License data | |
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| IUPHAR/BPS | |
| DrugBank |
|
| ChemSpider |
|
| UNII | |
| KEGG |
|
| ChEBI | |
| ChEMBL | |
| PDB ligand | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C23H26ClN7O3 |
| Molar mass | 483.96 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
Avanafil is aPDE5 inhibitor approved forerectile dysfunction by theFDA on April 27, 2012[2] and by EMA on June 21, 2013.[3] Avanafil is sold under the brand namesStendra andSpedra. It was invented at Mitsubishi Tanabe Pharma, formerly known as Tanabe Seiyaku Co.,[4] and licensed toVivus Inc., which partnered withMenarini Group to commercialise Spedra in over forty European countries, Australia, and New Zealand.[5] Metuchen Pharmaceuticals obtained exclusive rights within the United States.[6]
Avanafil acts by inhibiting a specificphosphodiesterase type 5 enzyme found in various body tissues, primarily in thecorpus cavernosum penis.[7] Other similar drugs aresildenafil,tadalafil andvardenafil. The advantage of avanafil is that it has very fastonset of action compared with other PDE5 inhibitors. It is absorbed quickly, reaching a maximum serum concentration in about thirty to forty-five minutes.[8] About two-thirds of the participants were able to engage insexual activity within fifteen minutes.[8]
Avanafil is used to treat erectile dysfunction (ED).[9]
Although avanafil is generally well tolerated, dose dependent adverse effects can occur.[8] The most common adverse effects includeheadache,flushing,nasopharyngitis,nasal congestion, andback pain.[8] While it is also uncommon, there is a potential for visual disturbances to occur in patients.[8]
Avanafilinhibits phosphodiesterase-5, preventing the degradation of cGMP.[10][11] The increased levels of cGMP causesvasodilation, resulting in an increased blood flow in the penis.[11] Avanafil's mechanism of action takes places oncenitric oxide is released, in association with sexual stimulation.[11]
Avanafil can be synthesized from a benzylamine derivative and a pyrimidine derivative:[4]
